-
Mashup Score: 0
Patients with locally advanced resected non–small-cell lung cancer present a high risk of relapse. Although adjuvant platinum–based chemotherapy has become the standard of care, the role of postoperative radiation therapy (PORT) has been controversial for years. In patients with incomplete resection, PORT should be proposed, on the basis of a strong consensus, despite the absence of randomized…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
Lung ART evaluated 3D conformal PORT after complete resection in patients who predominantly had been staged using (18F-FDG PET-CT and received neoadjuvant or adjuvant chemotherapy. 3-year disease-free survival was higher than expected in both groups, but PORT was not associated with an increased disease-free survival compared with no PORT. Conformal PORT cannot be recommended as the standard of…
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Results from Lung ART now published @TheLancetOncol. Initially presented at #ESMO20 by Dr. Cecile Le Pechoux, Lung ART showed no survival benefit with post operative radiotherapy (PORT) for completely resected N2+ NSCLC and changed practice for many. #LCSM https://t.co/UdXZkrxZg0
-
-
Mashup Score: 1Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial - 3 year(s) ago
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of poziotinib in patients with HER2 exon 20 mutant advanced NSCLC in a single-arm, open-label, phase II study. PATIENTS AND METHODS Patients with advanced HER2 exon 20 mutant NSCLC were enrolled to receive poziotinib at a dose of…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Published in #JCO @ASCO_pubs are results of poziotinib in #HER2 mutant NSCLC. This is a 30 pt cohort from @MDAndersonNews that predates the ZENITH20 study which was updated at #ESMO20. #LCSM @OncoAlert https://t.co/9ZhuHdRMQR
-
-
Mashup Score: 6
Karim Fizazi describes the OS benefit of the triplet.
Source: AnchorCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Uromigos: PEACE 1 has a survival advantage #esmo20 https://t.co/RTK6v0ycUE
-
PEACE1 overall survival in prostate cancer https://t.co/qBdhO2iuhx
-
PEACE 1 has a survival advantage #esmo20 https://t.co/RTK6v0ycUE
-
-
Mashup Score: 0Highlights from ESMO 2020 in gynecological cancers - 3 year(s) ago
Alexandra Leary, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the highlights in gynecological cancers from the European Society for…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We're eager to hear from the experts at #ESMO21 Satisfy your ESMO cravings by catching up on the learnings from #ESMO20 in #GynecologicalCancers with Alexandra Leary of @GustaveRoussy 👉https://t.co/InaQ0d0MiX👈 @VJOncology @myESMO #Gynsm #OvarianCancer #ESMO21
-
-
Mashup Score: 2ESMO highlights: genitourinary cancers - 3 year(s) ago
Yann-Alexandre Vano, Georges-Pompidou European Hospital, Paris, France, discusses his best bits within the European Society for Medical Oncology (ESMO) Virtual…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ahead of #ESMO21 check out last years highlights in #GU with Yann-Alexandre Vano of @HopitalPompidou Watch here 👉https://t.co/VGg34717Is👈 @VJOncology @myESMO #ESMO20 #GUsm #PCsm #BLCsm #KCsm #TSCsm #UroOnc #UroSoMe
-
-
Mashup Score: 5#ESMO20 Education Weekend regional talks: Asia-Pacific - 3 year(s) ago
This latest edition from our #ESMO20 Education Weekend Regional Talk series focused on highlights from the Asia-Pacific perspective. We asked panellists from…
Source: YouTubeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Experts from Asia-Pacific - J Tsang, @devnani_bharti @ravikanesvaran @herbloong @DrMeredithGT @reswong - shared how they translated key insights from #ESMO20 into daily practice & why resources are still highly relevant 👇 ▶️ https://t.co/lsytSUdo5v ⚙️ https://t.co/JM0zVVHlU3 https://t.co/wqeAiU3N4a
-
-
Mashup Score: 2Log In or Sign Up to View - 3 year(s) ago
See posts, photos and more on Facebook.
Source: www.facebook.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Asia-Pacific: #ESMO20 Education Weekend regional talk series. This Wednesday 12:00 CEST (18:00 HKT / 19:00 JST / 20:00 AEST) for educational highlights from regional perspectives. J Tsang, @ravikanesvaran @devnani_bharti @herbloong @DrMeredithGT & R Wong https://t.co/T3oQdXrNFO https://t.co/6iSelueIod
-
-
Mashup Score: 0#ESMO20 Education Weekend regional talks: Latin America - 3 year(s) ago
This latest edition from our #ESMO20 Education Weekend Regional Talk series focused on highlights from the Latin American perspective. We asked panellists fr…
Source: YouTubeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#LatinAmerica: Check out our latest edition from the #ESMO20 Education Weekend Regional Talk series, asking panellists from #LATAM for their key educational highlights from the event: https://t.co/4P7mxD4xSh All resources are available on OncologyPRO 👉https://t.co/OzyjR4vewg https://t.co/l0FkxFo92i
-
-
Mashup Score: 1#ESMO20: slides, webcasts, abstracts, videos & news - 3 year(s) ago
Slides, webcasts, abstracts, video interviews, medwireNews articles covering the ESMO Congress
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A great #LatinAmerica Talk focusing on the #ESMO20 education weekend!! Kudos to @E_de_Azambuja @Betzabe100 @demattosarruda @Martin_AngelMD @AndreaAnampaG and of course the amazing hardworking teat at @myESMO ‼️ https://t.co/A57EONa9Oh https://t.co/729MrcfCV9
-
We have seen major changes to use of post-operative radiotherapy (PORT) since the LungART data at #ESMO20 and its recent publication. Here, an overview of PORT, when appropriate (incomplete resection) and a look to the future (MRD assessment, biomarkers). https://t.co/qqvS3NW2il